Literature DB >> 9797246

Organism-dependent fungicidal activities of azoles.

E K Manavathu1, J L Cutright, P H Chandrasekar.   

Abstract

We investigated the antifungal activities of itraconazole and voriconazole on Aspergillus species by time kill studies, and the results were compared with those obtained for Candida species. Exposure of Aspergillus fumigatus conidia to varying concentrations (1.25 to 10 microg/ml) of itraconazole and voriconazole resulted in cellular death; the cytocidal effect was time and concentration dependent. In contrast, no killing of Candida albicans occurred in the presence of itraconazole and voriconazole at concentrations as high as 10 microg/ml, although candidal growth was inhibited compared to the drug-free control. Amphotericin B (1.25 to 10 microg/ml), on the other hand, killed both A. fumigatus and C. albicans. Similar results were obtained for non-A. fumigatus aspergilli and non-C. albicans Candida species. These observations indicate that both itraconazole and voriconazole are cytocidal agents for Aspergillus species but not for Candida species, suggesting that azoles possess organism-dependent fungicidal activities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797246      PMCID: PMC105986     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

2.  Non-sterol structural probes of the lanosterol 14 alpha-demethylase from Saccharomyces cerevisiae.

Authors:  G D Wright; T Parent; J F Honek
Journal:  Biochim Biophys Acta       Date:  1990-08-01

3.  Proton permeability induced by polyene antibiotics. A plausible mechanism for their inhibition of maltose fermentation in yeast.

Authors:  J Palacios; R Serrano
Journal:  FEBS Lett       Date:  1978-07-15       Impact factor: 4.124

4.  In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.

Authors:  K L Oakley; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 5.  Mechanisms and clinical impact of antifungal drug resistance.

Authors:  H Vanden Bossche; D W Warnock; B Dupont; D Kerridge; S Sen Gupta; L Improvisi; P Marichal; F C Odds; F Provost; O Ronin
Journal:  J Med Vet Mycol       Date:  1994

6.  In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species.

Authors:  J A Vazquez; M Lynch; J D Sobel
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

7.  A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus.

Authors:  E K Manavathu; G J Alangaden; S A Lerner
Journal:  Can J Microbiol       Date:  1996-09       Impact factor: 2.419

8.  Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent.

Authors:  J Heeres; L J Backx; J H Mostmans; J Van Cutsem
Journal:  J Med Chem       Date:  1979-08       Impact factor: 7.446

Review 9.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

10.  Yeast cytochrome P-450 catalyzing lanosterol 14 alpha-demethylation. I. Purification and spectral properties.

Authors:  Y Yoshida; Y Aoyama
Journal:  J Biol Chem       Date:  1984-02-10       Impact factor: 5.157

View more
  53 in total

Review 1.  Fungal resistance.

Authors:  H Bernhardt; K Zimmermann; M Knoke
Journal:  Infection       Date:  1999       Impact factor: 3.553

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 3.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

4.  Voriconazole: the newest triazole antifungal agent.

Authors:  Nickie D Greer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-04

5.  In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.

Authors:  Russell E Lewis; Nathan P Wiederhold; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 6.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.

Authors:  Joseph Meletiadis; Charalampos Antachopoulos; Theodouli Stergiopoulou; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

Review 8.  Newer antifungal agents.

Authors:  Walid Abuhammour; Eyassu Habte-Gaber
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

9.  Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents.

Authors:  E K Manavathu; J Cutright; P H Chandrasekar
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.